Fontolizumab Protein Design Labs

Current Opinion in Investigational Drugs

Volumn 6, Issue 5, 2005, Pages 537-544

  Dumont, Francis J ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; ADALIMUMAB; FONTOLIZUMAB; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; PLACEBO; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CROHN DISEASE; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FLU LIKE SYNDROME; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LYMPHOMA; MULTIPLE DRUG DOSE; NONHUMAN; PSORIASIS; REVIEW; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG DESIGN; DRUG INDUSTRY; HUMANS; INTERFERON TYPE II;

EID: 18144371659     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. 387632 PDL reports phase I results of SMART IFNγ Ab. Protein Design Labs Inc PRESS RELEASE 2000 October 30
2. 395717 Protein Design Labs announces phase I/II trial of SMART anti-γ interferon antibody in Crohn's disease. Protein Design Labs Inc PRESS RELEASE 2001 January 10
3. 443330 Humanizer Wire - Winter 2001. Protein Design Labs Inc COMPANY NEWSLETTER 2001 1 1
4. 450688 Protein Design Labs begins phase II trial of SMART anti-γ interferon antibody in Crohn's disease. Protein Design Labs Inc PRESS RELEASE 2002 May 08
5. 451111 Preliminary results of a phase I/II study of HuZAF, an anti-IFNγ monoclonal antibody, in patients with moderate to severe active Crohn's disease. Rutgeerts P, Reinisch W, Colombel JF, Gendre JP, Deventer SV, Oldenburg B, Modigliani R, Layug B, Cheng M, O'Connor J, Levitt D GASTROENTEROLOGY 2002 122 4 Suppl 1 Abs 505
6. 452003 Protein Design Labs presents phase I/II clinical results with SMART anti-γ interferon antibody in Crohn's disease. Protein Design Labs Inc PRESS RELEASE 2002 May 21
7. 452048 Digestive Disease Week 2002 (Part III) - Overnight Report, San Francisco, CA, USA. Veryard C IDDB MEETING REPORT 2002 May 19-22
8. 459264 Inhibition of Th1 responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45RBhi CD4+ T cells. Powrie F, Leach MW, Mauze S, Menon S, Caddie LB, Coffman RL IMMUNITY 1994 1 7 553-562
9. 466189 Inflammatory bowel disease. Podolsky DK N ENGL J MED 2002 347 6 417-429
10. 476587 Interferon-γ in autoimmunity. Billiau A CYTOKINE GROWTH FACTOR REV 1996 7 125-34
11. 482596 Inflammation in Drug Discovery and Development - SRI's Seventh International Meeting, San Diego, CA, USA. Braddock M IDDB MEETING REPORT 2003 February 20-21
12. 488784 Protein Design Labs - 2002 annual report. Protein Design Labs Inc ANNUAL REPORT 2003 April 08
13. 488991 Protein Design Labs - corporate presentation. Protein Design Labs Inc COMPANY PRESENTATION 2003 April 30
14. 490211 Protein Design Labs reports progress with three humanized antibodies in inflammatory bowel disease. Protein Design Labs Inc PRESS RELEASE 2003 May 19
15. 511332 Protein Design Labs announces third quarter 2003 financial results. Protein Design Labs Inc PRESS RELEASE 2003 November 03
16. 511461 Therapeutic value of α-4 integrin blockade in inflammatory bowel disease: The role of natalizumab. Ghosh S EXPERT OPIN BIOL THER 2003 3 6 995-1000
17. 513707 The Th1 immune pathway as a therapeutic target in Crohn's disease. Bamias G, Sugawara K, Pagnini C, Cominelli F CURR OPIN INVEST DRUGS 2003 4 11 1279-1286
18. 518854 HuZaF, a humanized anti-IFNγ antibody, inhibits chemokine production by activated T cells and intestinal epithelial cells and blocks chemotaxis of activated CXCR3+ lymphocytes. Tsao T, Li J, Woo J, Keller S, Klingbeil C, Vexler V DIG DIS WEEK 2003 125 Abs M1218
19. 518865 Pharmacology and safety evaluation of humanized monoclonal antibodies in the chimpanzee: Study design and conduct issues and application to clinical trials. Bullock C, Tang MT, Wang H, Klingbeil C INT J TOXICOLOGY 2002 21 6 532-533
20. 526730 Psoriasis. Lebwohl M LANCET 2003 361 9364 1197-1204
21. 528130 PDL unveils data on bowel disease portfolio. Protein Design Labs Inc PRESS RELEASE 2004 March 22
22. 530750 Tolerance, DCs and tryptophan: Much ado about IDO. Grohmann U, Fallarino F, Puccetti P TRENDS IMMUNOL 2003 24 5 242-248
23. 538242 Fontolizumab (HuZAF) pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and exposure/response relationship in patients (Pts) with moderate and severe Crohn's disease (CD). Ding H, Maia M, Keller S, Colombell JF, Van Deventer SJ, Gendre JP, Reinisch W, Rutgeerts P, Tang MT GASTROENTEROLOGY 2004 126 4 Suppl 2 Abs T1302
24. 566219 United European Gastroenterology Week - 12th Annual Meeting, Prague, Czech Republic. Beglinger C IDDB MEETING REPORT 2004 September 25-29
25. 578232 Anti-interleukin-12 antibody for active Crohn's disease. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Homung RL, Quezado M et al N ENGL J MED 2004 351 20 2069-2079
26. 579638 PDL updates status of clinical development programs & partnering objectives. Protein Design Labs Inc PRESS RELEASE 2005 January 12
27. 582555 Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Birt J, Paavola J, Lee SK, Price J, Targan SR, Abreu MT AM J GASTROENTEROL 2005 100 1 75-79
28. 587647 Cytokines: Promoters and dampeners of autoimmunity. Hill N, Sarvetnick N CURR OPIN IMMUNOL 2002 14 6 791-797
29. 587648 Interferon-γ: An overview of signals, mechanisms and functions. Schroder K, Hertzog PJ, Ravasi T, Hume DA J LEUKOCYTE BIOL 2004 75 2 163-189
30. 587651 The expanding universe of T-cell subsets: Th1, Th2 and more. Mosmann TR, Sad S IMMUNOL TODAY 1996 17 3 138-146
31. 587654 Modulation of Th1 and Th2 responses for immunotherapy. Dumont FJ EXPERT OPIN THER PAT 2002 12 3 341-367
32. 587655 Th1/Th2 cells in inflammatory disease states: Therapeutic implications. Moss RB, Moll T, EI-Kalay M, Kohne C, Soo Hoo W, Encinas J, Carlo DJ EXPERT OPIN BIOL THER 2004 4 12 1887-1896
33. 587661 Cytokines and transcription factors that regulate T helper cell differentiation: New players and new insights. Agnello D, Lankford CS, Bream J, Morinobu A, Gadina M, O'Shea JJ, Frucht DM J CLIN IMMUNOL 2003 23 3 147-161
34. 587662 Molecular mechanisms regulating Th1 immune responses. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH ANNU IMMUNOL 2003 21 713-758
35. 587663 Induced recruitment of NK cells to lymph nodes provides IFNγ for Th1 priming. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F NAT IMMUNOL 2004 5 12 1260-1265
36. 587788 Anti-interferon-γ antibodies in the treatment of autoimmune diseases. Skurkovich B, Skurkovich S CURR OPIN MOL THER 2003 5 1 52-57
37. 587791 Using single-gene deletions to identify checkpoints in the progression of systemic autoimmunity. Pollard KM, Hultman P, Kono DH ANN NY ACAD SCI 2003 987 236-239
38. 587792 The integrity of the ball-and-socket joint between V and C domains is essential for complete activity of a humanized antibody. Landolfi NF, Thakur AB, Fu H, Vasquez M, Queen C, Tsurushita N J IMMUNOL 2001 166 3 1748-1754
39. 587797 Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Jacob SE, Nassiri M, Kerdel FA, Vincek V MEDIATORS INFLAMM 2003 12 5 309-313
40. 587799 Psoriasis vulgaris: Cutaneous lymphoid tissue supports T-cell activation and 'Type 1' inflammatory gone expression. Lew W, Bowcock AM, Krueger JG TRENDS IMMUNOL 2004 25 6 295-305
41. 587805 The immunological and genetic basis of inflammatory bowel disease. Bouma G, Strober W NAT IMMUNOL 2003 3 7 521-533
42. 587811 A potent neutralizing monoclonal antibody can discriminate amongst IFNγ from various primates with greater specificity than can the human IFNγ receptor complex. Thakur AB, Landolfi NF MOL IMMUNOL 1999 36 15-16 1107-1115
43. 587814 Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-γ-interferon antibody. Fan ZC, Shan L, Goldsteen BZ, Guddat LW, Thakur A, Landolfi NF, Co MS, Vasquez M, Queen C, Ramsland PA, Edmundson AB J MOL RECOGNIT 1999 12 1 19-32
44. 587821 Three-dimensional structures of a humanized anti-IFNγ Fab (HuZAF) in two crystal forms. Bourne PC, Terzyan SS, Cloud G, Landolfi NF, Vasquez M, Edmundson AB ACTA CRYSTALLOGR D BIOL CRYSTALLOGR 2004 60 10 1761-1769
45. 587823 Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. Xie JH, Nomura N, Lu M, Chen SL, Koch GE, Weng Y, Rosa R, Di Salvo J, Mudgett J, Peterson LB, Wicker LS, DeMartino JA J LEUKOCYTE BIOL 2003 73 6 771-780
46. 587826 Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group LANCET 2002 359 9317 1541-1549
47. 587837 Recent developments in the pharmacological treatment of Crohn's disease. Srinivasan R, Lichtenstein GR EXPERT OPIN INVESTIG DRUGS 2004 13 4 373-391
48. 587842 Influence of immunogenicity on the long-term efficacy Of infliximab in Crohn's disease. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P N ENGL J MED 2003 348 7 601-608
49. 587844 Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Sandborn WJ CURR GASTROENTEROL REPORTS 2003 5 6 501-505
50. 587853 How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease. Sandbom WJ REV GASTROENTEROLOGICAL DISORDERS 2004 4 Suppl 3 S25-S33
51. 587869 Clinical implications of inflammatory bowel disease genetics on phenotype. Cummings JR, Jewell DP INFLAMM BOWEL DIS 2005 11 1 56-61
52. 587872 The IL-12 family of heterodimeric cytokines: New players in the regulation of T cell responses. Trinchieri G, Pflanz S, Kastelein RA IMMUNITY 2003 19 5 641-644
53. 587873 IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ J EXP MED 2005 201 2 233-240
54. 587874 Paradoxical roqles of IFNγ in models of Th1-mediated autoimmunity. Rosloniec EF, Latham K, Guedez YB ARTHRITIS RES 2002 4 6 333-336
55. 587878 Anti-inflammatory properties of pro-inflammatory interferon-γ. Muhl H, Pfeilschifter J INT IMMUNOPHARMACOL 2003 3 9 1247-1255
56. 587878 New cytokine therapeutics for inflammatory bowel disease. Stokkers PC, Hommes DW CYTOKINE 2004 28 4-5 167-173
57. 587881 Inhibition of IFNγ-inducible proteIn-10 abrogates colitis in IL-10-/-mice. Singh UP, Singh S, Taub DD, Lillard JW Jr J IMMUNOL 2003 171 3 1401-1406
58. 589547 Fontolizumab (HuZAF), a humanized anti-IFNγ antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's disease. Hommes D, Mikhajlova T, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zakuiova M, D'Haens G, Van Asche G, Pearce T GASTROENTEROLOGY 2004 127 4 Suppl 2 Abs Late 5
59. 589575 PDL announces webcast of R&D update at 8:00AM Eastern Time, October 15. Protein Design Labs Inc PRESS RELEASE 2004 October 11
60. 589588 Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn's disease: A prospective cohort study. Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P GASTROENTEROLOGY 2003 125 1 32-39
61. 589815 Protein Design Labs - product development pipeline. Protein Design Labs Inc COMPANY WORLD WIDE WEB SITE 2005 March 15
62. 592477 Elan and Biogen Idec announce TYSABRI update. Elan Corp plc PRESS RELEASE 2005 March 30
63. 592581 IL-12, but not IFNγ, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. Davidson NJ, Hudak SA, Lesley RE, Menon S, Leach MW, Rennick DM J IMMUNOL 1998 161 6 3143-3149
64. 592584 Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFNγ receptor-deficient mice. Camoglio L, te Velde AA, de Boer A, ten Kate FJ, Kopf M, van Deventer SJ EUR J IMMUNOL 2000 30 5 1486-1495
65. 592585 Evidence for the critical role of interleukin-12 but not interferon-γ in the pathogenesis of experimental colitis in mice. Tozawa K, Hanai H, Sugimoto K, Baba S, Sugimura H, Aoshi T, Uchijima M, Nagata T, Koide Y J GASTROENTEROL HEPATOL 2003 18 5 578-587